^
Association details:
| Biomarker: | PTEN deletion |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Transcriptomic Signatures Associated With Outcomes in Recurrent Prostate Cancer Treated With Salvage Radiation, Androgen-Deprivation Therapy, and Enzalutamide: Correlative Analysis of the STREAM Trial
Published date:
08/18/2023
Excerpt:
We performed a retrospective analysis of a prospective phase II multicenter trial of enzalutamide, ADT, and salvage radiotherapy in men with rising PSA after RP....Men with signatures of PTEN loss (hazard ratio [HR], 1.32; 95% CI, 1.07 to 1.64; P = .01) or HRD (HR, 1.21; 95% CI, 1.05 to 1.39; P = .009) had worse PFS...
DOI:
10.1200/PO.23.00214
Source:
Title:
Circulting Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer
Published date:
03/26/2021
Excerpt:
Men who had progression-free survival of ≤3 months despite enzalutamide/abiraterone treatment were more likely to have baseline CTC genomic loss of CHD1, PTEN, PHLPP1, and ZFHX3 and gains of BRCA2, KDM5D, MYCN, and SPARC.
DOI:
10.1158/1541-7786.MCR-20-0975
Trial ID:
